Current Landscape and Future Directions of Multi-specific Antibodies

Sponsored by: Sino Biological

C.E. Credits: P.A.C.E. CE ｜ Florida CE

Speaker

Event Date & Time

Date: August 10, 2023

Time: 8:00 AM (PST), 11:00 AM (EST), 5:00 PM (CET)

Abstract

Antibody therapeutics is a fast-growing market boosted by developments in bispecific antibodies and in newly emerging tetra-specific antibodies. With the ability to recruit a combination of antibody conjugates and immune cells to target cells, as well as the capacity to bind multiple epitopes simultaneously, multi-specific antibodies are equipped with an improved level of specificity. Moreover, the multi-valency of these antibodies enables enhanced targetability and efficacy. This webinar outlines recent advancements in developing multi-specific antibodies and their applications in various diseases from cancer to infectious diseases. It will also present the preclinical developments and clinical testing approvals for this antibody therapy. Furthermore, this webinar will discuss the challenges and barriers in advancing this very promising therapy, and where the current research is headed to overcome these challenges. As a leading bioreagents company, Sino Biological offers a multitude of products and services to help advance antibody therapy preclinical research.

Learning Objectives

Overview of multi-specific antibody therapy
Discuss the new advancements in antibody therapeutics and multi-specific antibody therapy
Summarize clinical trials landscape
Review challenges and future directions for multi-specific antibody therapyresearch and development

Webinars will be available for unlimited on-demand viewing after live event.

Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Current Landscape and Future Directions of Multi-specific Antibodies

Shebna Massey, PhD